Revenue and Profit Growth - Revenue for 2023 reached RMB 7,360,262,000, a 13.5% increase from RMB 6,486,277,000 in 2022[2] - Gross profit increased to RMB 2,055,704,000 in 2023, up 14.6% from RMB 1,793,386,000 in 2022[2] - Net profit rose to RMB 842,548,000 in 2023, a 26.5% increase from RMB 666,182,000 in 2022[2] - Total revenue for 2023 reached RMB 7,360,262 thousand, an increase from RMB 6,486,277 thousand in 2022[15] - Revenue increased by 13.5% from approximately RMB 6,486,277 thousand in 2022 to approximately RMB 7,360,262 thousand in 2023, driven by a large order in the oil refining industry[84] - Gross profit grew by 14.6% from approximately RMB 1,793,386 thousand in 2022 to approximately RMB 2,055,704 thousand in 2023, with a stable gross margin of 27.9%[89] - Net profit increased by 26.5% to RMB 842,548 thousand, with a net profit margin of 11.4%, up from 10.3% in 2022[103] - Adjusted EBITDA for the year ended December 31, 2023, was approximately RMB 1,143,066 thousand, a 28.3% increase from RMB 890,682 thousand in 2022[105][106] New Orders and Business Segments - Newly signed orders amounted to RMB 7,784,856,000 in 2023, a decrease of 16.8% from RMB 9,355,794,000 in 2022[2] - Revenue from modular pressure equipment grew significantly to RMB 4,553,792 thousand in 2023, up from RMB 3,648,656 thousand in 2022[15] - The company's new order intake for the pharmaceutical and biopharmaceutical sector accounted for 33.47% of total new orders, with a value of RMB 2,605,267 thousand[68] - The chemical industry contributed 21.42% to the company's new order intake, amounting to RMB 1,667,796 thousand[68] - The electronic chemicals sector represented 14.95% of new orders, with a value of RMB 1,164,186 thousand[68] - The company's total new order intake for the year reached RMB 7,784,856 thousand, with the pharmaceutical and biopharmaceutical sector being the largest contributor[68] - The pharmaceutical and biopharmaceutical sector contributed RMB 2,228,092 thousand, accounting for 30.3% of total revenue, with a year-on-year increase of 3.4%[85] - The oil refining sector saw a significant revenue increase of 502.9%, contributing RMB 971,601 thousand, up from RMB 161,158 thousand in 2022[85] Financial Position and Assets - Total assets minus current liabilities increased to RMB 4,661,063,000 in 2023 from RMB 3,081,176,000 in 2022[7] - Cash and cash equivalents stood at RMB 2,168,682,000 in 2023, a 58.2% increase from RMB 1,370,359,000 in 2022[7] - Property, plant, and equipment grew to RMB 2,105,463,000 in 2023, up 30.8% from RMB 1,609,565,000 in 2022[6] - Equity attributable to shareholders of the company increased to RMB 4,382,491,000 in 2023 from RMB 2,815,730,000 in 2022[9] - Total equity rose to RMB 4,390,609,000 in 2023, a 55.5% increase from RMB 2,822,646,000 in 2022[9] - The company's total equity increased from RMB 990.669 million at the beginning of 2022 to RMB 2,093.434 million by the end of 2023, reflecting significant growth in capital and reserves[52] - Property, plant, and equipment increased by 30.8% to RMB 2,105,463 thousand as of December 31, 2023, driven by construction investments in the Suzhou manufacturing base[107] - Trade and other receivables grew by 28.6% to RMB 1,499,372 thousand as of December 31, 2023, due to increased revenue[108] - Inventory decreased by 18.7% to RMB 1,800,466 thousand as of December 31, 2023, as large orders were in the early design phase[109] - Contract liabilities decreased by 20.8% to RMB 2,290,334 thousand as of December 31, 2023, due to revenue recognition from 2022 orders and new 2023 orders not yet reaching payment milestones[110] - Total borrowings decreased by 17.8% to RMB 365,083 thousand as of December 31, 2023, with a debt-to-equity ratio dropping to 8.3% from 15.7% in 2022[111] - Cash and cash equivalents increased by RMB 798,323 thousand to RMB 2,168,682 thousand as of December 31, 2023[112] Costs and Expenses - Employee benefits and salaries increased to RMB 1,128,338 thousand in 2023, compared to RMB 857,619 thousand in 2022[23] - R&D costs increased to RMB 418.149 million in 2023, up from RMB 316.084 million in 2022, with employee costs accounting for RMB 194.026 million (2022: RMB 155.469 million)[25] - Inventory costs rose to RMB 5.304 billion in 2023, compared to RMB 4.692 billion in 2022, including employee costs of RMB 628.22 million (2022: RMB 538.824 million)[26] - Depreciation expenses for property, plant, and equipment increased to RMB 116.263 million in 2023 from RMB 89.668 million in 2022[25] - Current tax provision for the year amounted to RMB 126.422 million in 2023, up from RMB 96.623 million in 2022[27] - Deferred tax liabilities increased to RMB 15.364 million in 2023, compared to a reversal of RMB 1.888 million in 2022[27] - R&D expenses grew by 32.3% to RMB 418,149 thousand, accounting for 5.7% of total revenue, up from 4.9% in 2022[100] - Sales and marketing expenses decreased by 5.0% to RMB 175,228 thousand, accounting for 2.4% of total revenue, down from 2.8% in 2022[98] - General and administrative expenses rose by 6.4% to RMB 543,143 thousand, accounting for 7.4% of total revenue, down from 7.9% in 2022[99] - Income tax expenses surged by 49.7% to RMB 141,786 thousand, with an effective tax rate of 14.4%, up from 12.5% in 2022[102] International Business and Market Expansion - Revenue from the North American market increased to RMB 863,532 thousand in 2023, compared to RMB 515,899 thousand in 2022[20] - Revenue from Asia (excluding Mainland China) rose to RMB 1,824,800 thousand in 2023, up from RMB 1,007,267 thousand in 2022[20] - The company's overseas business exceeded expectations, with a rebound in demand, leading to confidence in steady growth for 2024 despite a slowdown in new order intake[70] - The company established Pharmadule Singapore with a registered capital of SGD 3,000,000 to support life sciences business expansion in Southeast Asia[114] - Morimatsu Singapore acquired 100% of Morimatsu T&S, which has a registered capital of JPY 100 million, to support energy materials business[115] - Lifesciences Singapore was established with a registered capital of SGD 300,000 to support overseas expansion of the life sciences business[115] - The company directly retains 51% of the shares and gains control of the joint venture, Morimatsu Dialog, to strengthen management synergy[116] - The subsidiary, Morimatsu Engineering, acquired 100% equity of Shandong Keda Chemical Engineering Co., Ltd[116] - Morimatsu T&S subscribed to 140,056 preferred shares of 3DC Corporation for a total of 49,999,992 JPY, holding 2.82% equity post-subscription[116] - The company established a new wholly-owned subsidiary, Morimatsu International Investment Limited (MII), with a registered capital of 10,000 HKD[117] Projects and Innovations - The company secured a contract for a biofuel modular plant project, expected to process 200,000 tons of non-recyclable waste annually and produce 125 million liters of biofuel and renewable chemicals[73] - The company successfully delivered core equipment for a biofuel project, contributing to the production of sustainable aviation fuel and biogas from waste materials[74] - The company signed a contract for a battery raw materials project, marking the first overseas deployment of its lithium hexafluorophosphate technology[75] - The company completed the delivery of a ternary cathode material project, advancing new kiln technology in the lithium battery industry[75] - The company delivered a refinery expansion project, including 150 core equipment units and 100 modules, marking its largest refinery project order from the client[76] - The company signed a contract for a 40,000-ton/year ethylene acrylic acid (EAA) plant, breaking the monopoly of ultra-high-pressure equipment manufacturing in Europe and the US[77] - The company successfully shipped a customized molten salt reaction system, achieving domestic substitution and showcasing its capabilities as a comprehensive solution provider[77] - The company delivered the world's largest injection-grade recombinant human albumin fermentation system, capable of producing approximately 100 tons annually[79] - A modular pharmaceutical factory project for an international pharmaceutical company was successfully shipped, covering a total construction area of approximately 5,000 square meters[79] - The Malaysia manufacturing base expansion project, with an investment of approximately USD 60 million, focuses on producing equipment for electric vehicle raw materials, semiconductors, and green energy[82] - The Changshu manufacturing base, covering approximately 130,000 square meters, was fully delivered in Q4 2023 and is ready for production, targeting the biopharmaceutical and high-purity industries[83] - The company successfully delivered a plastic recycling project for an international client, utilizing chemical recycling to produce high-purity food-grade PET[80] - The Malaysia manufacturing base achieved a milestone with the first module project shipment for high-purity sulfuric acid used in large-scale integrated circuits[81] Corporate Governance and Shareholder Information - The company's Chinese subsidiaries benefit from a preferential tax rate of 15% due to their high-tech enterprise status[32] - The company recognized a deferred tax liability of RMB 14.921 million for a 10% withholding tax on dividends of RMB 150 million to be distributed by a subsidiary[33] - Basic earnings per share increased to RMB 0.726 in 2023, calculated based on a net profit of RMB 844.684 million and 1.163 billion weighted average shares[35] - The company's subsidiaries in Sweden, the US, India, Japan, Italy, and Mexico are subject to corporate tax rates ranging from 20.6% to 33.58%[29][30] - The company's subsidiaries in Singapore are subject to a 17% corporate tax rate, but no provision was made as they had no taxable income in 2023[31] - Weighted average number of shares increased from 1,050,774,000 in 2022 to 1,163,300,000 in 2023[36] - Diluted earnings per share calculated based on a profit attributable to shareholders of RMB 844,684,000 in 2023, up from RMB 669,266,000 in 2022[37] - The company did not declare or approve any dividends for the years ending December 31, 2022, and 2023[58] - The board proposed a final dividend of HKD 0.1 per share for the year ended December 31, 2023, subject to shareholder approval[119] - The company will hold its Annual General Meeting on June 18, 2024, and will suspend share registration from June 13 to June 18, 2024[120] - The company has not purchased, sold, or redeemed any of its listed securities during the reporting period[121] - The company has complied with the Corporate Governance Code and has not deviated from its provisions during the reporting period[122] - The company has appointed KPMG as its auditor for the reporting period and will propose its reappointment at the Annual General Meeting[125] Other Financial Metrics - The company's remaining performance obligations as of December 31, 2023, amounted to RMB 9,077,735 thousand, indicating future revenue to be recognized over the next 12 to 36 months[18] - Government grants increased significantly to RMB 28,090 thousand in 2023, compared to RMB 3,306 thousand in 2022[22] - Interest income rose to RMB 59,765 thousand in 2023, up from RMB 15,259 thousand in 2022[22] - The company's financial costs decreased to RMB 13,291 thousand in 2023, down from RMB 15,951 thousand in 2022[23] - Contract assets increased to RMB 866,310,000 in 2023 from RMB 830,927,000 in 2022[40] - Trade and other payables increased to RMB 1,669,850,000 in 2023 from RMB 1,633,543,000 in 2022[49] - Trade payables aged within three months decreased to RMB 761,296,000 in 2023 from RMB 1,005,728,000 in 2022[50] - The exchange reserve increased by RMB 25.531 million in 2023, compared to an increase of RMB 615,000 in 2022[52] - The company's share capital increased from RMB 643.657 million at the beginning of 2023 to RMB 1,302.751 million by the end of the year, driven by share issuances and exercises of share options[53] - The capital reserve increased by RMB 36.221 million in 2023, primarily due to equity-settled share-based payments[52] - The company's total equity changes in 2023 amounted to RMB 919.194 million, driven by net profit, share issuances, and other comprehensive income[52] - The company's financial assets are categorized into three levels of fair value measurement: Level 1 (active market quotes), Level 2 (observable inputs without significant unobservable inputs), and Level 3 (significant unobservable inputs)[62] - As of December 31, 2023, the fair value of Level 2 forward foreign exchange contracts is estimated based on the current forward prices from the Bank of China[65] - The company invested RMB 10,000,000 to acquire a 1.75% equity stake in Quanxin Quanyi (Shanghai) Life Technology Co., Ltd., classified as a financial asset at fair value through profit or loss[66] - The cost of treasury shares repurchased for equity-settled share-based payments in 2023 was RMB 37.110 million, slightly higher than the RMB 36.581 million in 2022[55] - A total of 9,327,555 restricted share units were vested and exercised in 2023, with a value of RMB 34.056 million[56] - The company issued 80 million shares in 2023, raising RMB 567.206 million in net proceeds[54] - As of December 31, 2023, the company had nearly 4,500 employees, including over 650 R&D personnel, accounting for more than 14% of the total workforce[118]

| --- | --- | |-----------------------------------------------------------------------------------------------------------------|----------------------------------------------| | | | | Morimatsu International Holdings Company Limited 森松國際控股有限公司 (於香港註冊成立的有限公司) 股份代號：2155 | ...... . . ------------------ .. . . . . . | | e | O | | Q | | | 0 Q e 9 | 中 期 報 告 | | Q | 0 ■■ | 目錄 | --- | --- | |--------------------------|-------| | | | | 公司信息 | 2 | | 釋義及詞彙 | 4 | | 管理層討論與分析 | 8 | | 補充資料 | 39 | | 綜合損益表 | 43 | | 綜合損益及其他 ...

[0 -> 22] 大家好欢迎参加三松国际2023年中期业绩发表会目前所有参会者均处于静音发牌下面开始播报免责声明本次会议仅服务于参会的广大投资者 [23 -> 41] 关于音频及文字记录的内容仅供参会者内部使用不得公开发布深松国际未授权任何媒体转发本次会议相关内容未经允许和授权的转载转发均属侵权深松国际将保留追究其法律责任的权利 [41 -> 66] 森松国际不承担因转载转发而产生的任何损失和责任市场有风险投资需谨慎提醒广大投资者谨慎做出投资决策在主讲嘉宾发言结束后将留体问时间有请现场主持人诸位投资人诸位券商的分析师老师大家晚上好我是森松国际的邵叶 [66 -> 95] 非常感谢诸位在百忙之中抽出时间参加我们今天的业绩交流会也非常感谢大家对森松国际的关注特别是感谢我们的券商合作伙伴在各种场合对森松国际的推荐和支持从今年开始是公司上市的第三年我们也请诸位给予我们更多的关注和教育让森松国际始终有机会和大家保持沟通也欢迎诸位共同见证我们的发展与成长 [96 -> 124] 首先请允许我向诸位介绍今天与会的管理层成员首先是执行董事森松国际高级副总裁材料与能源板块负责人盛燕盛总森松国际副总高级副总裁陆伟峰陆总森松国际 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Morimatsu International Holdings Company Limited 森松國際控股有限公司 （於 香 港 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2155） 截至2023年6月30日止六個月的中期業績公告 森松國際控股有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然向本公司 股東公布本公司及其附屬公司（統稱「本集團」）截至2023年6月30日止六個月（「中 期期間」或「報告期」）的未經審核綜合中期業績。 | --- | --- | --- | |------------------------------------------|-------------------------------------------|-------------------------------------| | | | | | | | | | | 截至 6 月 30 ...

ur Needs · Our Drive | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------|-------|------------------------------------------------|-------| | Morimatsu International Holdings Company Limited 森松國際控股有限公司 (於香港註冊成立的有限公司) 股份代號：2155 | | ..... . ■ . . . . . . . . ... .. ..... . . . | | | | ■ 0 | | | | G Q | | 年 報 | | | G Q Q | 0 | | | | Q | | ■ ■ | | | --- | --- | --- | --- | --- | |---------------------------------|-------|--- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Morimatsu International Holdings Company Limited 森松國際控股有限公司 （於 香 港 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2155） 截至2022年12月31日止年度的 年度業績公告 | --- | --- | --- | |-------------------------------------------|-------------------------------------------------------------|----------------------------------------------------| | | | | | 財務摘要 | | | | | 截至 12 月 31 2022 年 人民幣元 | 日止年度 2021 年 人民幣元 （經重列 附註 1 ） | | 收益 毛利潤 | 6,486,27 ...